Dr. Ruan on the Future of Lenalidomide/Rituximab in MCL

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the future evaluation of lenalidomide (Revlimid) plus rituximab (Rituxan; R²) in mantle cell lymphoma (MCL).

The results of a 7-year analysis from a multicenter, phase 2 trial (NCT01472562), which were presented virtually during the 2020 ASH Annual Meeting and Exposition, demonstrated high rates of complete responses with R² as initial treatment in younger and elderly patients with MCL.

Although more data are needed, the durability of these responses suggests that some patients could be cured with R², says Ruan. A randomized clinical trial should evaluate the combination in a larger patient population vs immunotherapy or BTK inhibitors, which are standard options in MCL, concludes Ruan.